title: Suppression of matrix metalloproteinase production from nasal fibroblasts by fluticasone propionate in vitro.
abstract: OBJECTIVE
  To examine the influence of fluticasone propionate (FP) on matrix metalloproteinase (MMP) production from nasal polyp fibroblasts in vitro.
  
  
  METHODS
  Fibroblasts derived from five nasal polyps were stimulated with tumor necrosis factor (TNF)-alpha in the presence of various concentrations of FP. The influence of FP on MMP production was assessed by examining the levels of MMP-2 and -9 in culture supernatants using ELISA. We also examined the influence of FP on MMP mRNA expression using reverse transcriptase polymerase chain reaction.
  
  
  RESULTS
  The addition of FP caused significant suppression of MMP-2 and -9 production from nasal polyp fibroblasts in response to TNF-alpha stimulation. MMP mRNA expression was also suppressed by the addition of FP to cell cultures. The minimum concentration of the agent required to cause suppression was 10(-5) M.
  
  
  CONCLUSIONS
  These results suggest that the inhibitory action of FP on tissue remodeling may underlie the clinical efficacy of corticosteroids in nasal polyposis.
authors.affiliation: Department of Otolaryngology, School of Medicine, Showa University, Tokyo 142-8666, Japan.
authors.forename: Mayumi
authors.initials: M
authors.lastname: Namba
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Asano
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Kanai
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Kyo
authors.forename: So
authors.initials: S
authors.lastname: Watanabe
authors.forename: Tadashi
authors.initials: T
authors.lastname: Hisamitsu
authors.forename: Harumi
authors.initials: H
authors.lastname: Suzaki
mesh_terms: D000328:Adult; D000730:Androstadienes / Q000494:pharmacology* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002478:Cells, Cultured; D005260:Female; D005347:Fibroblasts / Q000187:drug effects* / Q000201:enzymology; D000068298:Fluticasone; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006801:Humans; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D009298:Nasal Polyps / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology*; D012333:RNA, Messenger / Q000378:metabolism; D019714:Tissue Inhibitor of Metalloproteinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism
chemical_list: D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D061965:Matrix Metalloproteinase Inhibitors; D012333:RNA, Messenger; D019714:Tissue Inhibitor of Metalloproteinases; D000068298:Fluticasone; D020782:Matrix Metalloproteinases